SCHEMBL679223

SCHEMBL679223

O=C(Nc1ccc(Nc2ccnc3[nH]c(=O)ccc23)cc1)c1cccc(F)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 14/20 0.70
AURKB Q96GD4 9/20 0.70
MEN1 O00255 1/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
KMT2A Q03164 1/20 0.54
DNMT1 P26358 1/20 0.53
DNMT3A Q9Y6K1 1/20 0.53
CHEK2 O96017 2/20 0.53
RET P07949 2/20 0.53
FLT4 P35916 2/20 0.53
LIMK1 P53667 2/20 0.53
MAPK13 O15264 1/20 0.53
NTRK1 P04629 1/20 0.53
HCK P08631 1/20 0.53
FGFR1 P11362 1/20 0.53
SIK1 P57059 1/20 0.53
TNK2 Q07912 1/20 0.53
WNK3 Q9BYP7 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL677909 0.90 AURKA (0.67) AURKAAURKBDNMT1DNMT3ACHEK2
SCHEMBL678958 0.88 AURKA (0.54) AURKAAURKBNPC1RAB9AKMT2A
SCHEMBL678875 0.87 AURKA (0.67) AURKAAURKBMEN1KMT2ADNMT1
SCHEMBL677593 0.87 AURKA (0.68) AURKAAURKBDNMT1DNMT3ACHEK2
SCHEMBL678945 0.86 AURKA (0.68) AURKAAURKBDNMT1DNMT3ACHEK2
SCHEMBL679458 0.86 AURKA (0.69) AURKAAURKBDNMT1DNMT3ACHEK2
SCHEMBL677356 0.84 AURKA (0.71) AURKAAURKBCHEK2RETFLT4
SCHEMBL679214 0.84 AURKA (0.64) AURKAAURKBDNMT1DNMT3ACHEK2
SCHEMBL682900 0.83 AURKA (0.54) AURKAAURKBMEN1NPC1RAB9A
SCHEMBL679045 0.83 AURKA (0.69) AURKAAURKBCHEK2RETFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-11-03 US claimed
JP-2011526912-A 2011-10-20 JP claimed
EP-2291376-A2 NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS Merck Patent GmbH (DE) 2011-03-09 EP claimed
WO-2010002779-A2 NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS MERCK SERONO S.A. (CH) 2010-01-07 WO claimed
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-11-03 US disclosed
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-11-03 US disclosed
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-11-03 US disclosed
EP-2291376-A2 NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS Merck Patent GmbH (DE) 2011-03-09 EP disclosed
WO-2010002779-A2 NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS MERCK SERONO S.A. (CH) 2010-01-07 WO disclosed
WO-2010002779-A2 NAPHTHYRIDININONES AS AURORA KINASE INHIBITORS MERCK SERONO S.A. (CH) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269758-A1 NAPHTHYRIDINONES AS PROTEIN KINASE INHIBITORS AURKA, AURKC, AURKB AURKA 1/4885AURKB 3/4885MEN1 1490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.